Dr. Eve Mylchreest to Lead Reproductive Toxicology Research at Southern Research

BIRMINGHAM, Ala., Sept. 9 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that Eve Mylchreest, Ph.D., has joined the Birmingham-based not-for-profit research organization to lead its reproductive toxicology group. Reproductive toxicology is the study of the effects of drugs and chemicals on mammalian reproduction, from the developing embryo/fetus to the sexually mature organism.  Reproductive toxicology is a critical component of drug development to ensure that new drug candidates do not cause harm to unborn children and to ensure that they do not impair the ability to have children.  

"We are very pleased to have Dr. Mylchreest join us, providing her significant expertise to our drug discovery and preclinical drug development efforts," said Dr. Andrew Penman, vice president of Drug Development at Southern Research.  "Her knowledge of reproductive toxicology and general toxicology, as well as her experience on drug development teams will be extremely valuable to our research clients."

Dr. Mylchreest has 13 years' experience as a study director conducting Good Laboratory Practices (GLP) studies for drugs, pesticides and commodity chemicals. She was previously employed by Pfizer in Chazy, NY, where she was a principal research scientist in Reproductive Toxicology.  Prior to that, she was a senior research toxicologist and manager at DuPont Haskell Laboratory in Newark, Del.  She completed her postdoctoral research at the Chemical Industry Institute of Toxicology in Research Park, NC.  Dr. Mylchreest earned her Bachelor's degree in biochemistry from the Universite de Montreal, Canada, also earning her Master's degree and Doctorate degrees in toxicology while there.

ABOUT SOUTHERN RESEARCH

Southern Research Institute, founded in 1941, is an independent non-profit organization conducting research and development in drug discovery and preclinical drug development, and advanced engineering research and development in materials, electromechanical systems design, and environmental and energy technologies.  Southern Research has discovered more than 20 drugs that have entered clinical trials, with seven drugs having been approved by the FDA for use in the treatment of cancer.  

More than 550 employees support commercial and government clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy sectors through technology out-licensing, sponsored research, and strategic collaborations.  Headquartered in Birmingham, Ala., Southern Research has facilities in Wilsonville, Ala., Frederick, Md., and Durham, NC and offices in Huntsville, Ala., New Orleans, La., Washington, DC and Kiev, Ukraine. For more information about Southern Research, visit www.SouthernResearch.org.

SOURCE Southern Research Institute